SPYRAL HTN-ON MED Study
Research type
Research Study
Full title
Global Clinical Study of Renal Denervation with the Symplicity Spyral™ multi-electrode renal denervation system in patients with uncontrolled hypertension on standard medical therapy
IRAS ID
180561
Contact name
Mustapha El Amrani
Contact email
Sponsor organisation
Medtronic
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 5 months, 31 days
Research summary
The purpose of this study is to provide additional information about a medical device intended to help treat high blood pressure in patients whose blood pressure is not controlled, despite treatment with three blood pressure medications. A recent study (SYMPLICITY HTN-3) conducted by Medtronic showed that the previous Symplicity™ renal denervation system, which included a similar radiofrequency generator and a single (one) electrode SymplicityTM catheter was safe, but it did not lower blood pressure as expected. The SYMPLICITY HTN-3 study was done in a different hypertensive patient population that required all patients to be on at least three antihypertensive medications at the highest dose the patients could tolerate. In that study, patients who were treated with renal denervation had a total of about 11 single electrode treatments. A similar decrease in blood pressure was seen after 6 months in the patients who received renal denervation and in the patients treated only with medications. Renal denervation in this study was found to be safe. The learnings from that study are being tested in the current study and include a more extensive treatment with a different catheter. The device in this study uses up to 4 electrodes at a time to deliver the same kind of energy in a specific pattern to disrupt the nerves. This study will be “Randomized” meaning that patients who meet the study criteria will be randomly assigned to one of the two groups. The study is “Controlled” meaning half of the patients will be treated with the device (the “Denervation Group”) and the other half will NOT be treated with the device (the “Control Group”). Each patient has a 50% chance of being assigned to the Denervation Group. This study is also “Blinded” meaning that patients will not be told which group they are assigned to, and certain procedures will be followed to prevent patients from knowing which group they are in until the specified time point.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
15/EE/0263
Date of REC Opinion
31 Jul 2015
REC opinion
Unfavourable Opinion